A1 Journal article – refereed

Automated GMP production and long-term experience in radiosynthesis of CB(1)tracer [F-18]FMPEP-d(2)

List of Authors: Salla Lahdenpohja, Thomas Keller, Sarita Forsback, Tapio Viljanen, Esa Kokkomäki, Riikka V. Kivelä, Jörgen Bergman,Olof Solin, Anna K. Kirjavainen

Publisher: WILEY

Publication year: 2020

Journal: Journal of Labelled Compounds and Radiopharmaceuticals


Journal acronym: J LABELLED COMPD RAD

Volume number: 63

Issue number: 9

Number of pages: 11

ISSN: 0362-4803

eISSN: 1099-1344

DOI: http://dx.doi.org/10.1002/jlcr.3845

Here, we describe the development of an in-house-built device for the fully automated multistep synthesis of the cannabinoid CB(1)receptor imaging tracer (3R,5R)-5-(3-([F-18]fluoromethoxy-d(2))phenyl)-3-(((R)-1-phenylethyl)amino)-1-(4-(trifluoromethyl)phenyl)pyrrolidin-2-one ([F-18]FMPEP-d(2)), following good manufacturing practices. The device is interfaced to a HPLC and a sterile filtration unit in a clean room hot cell. The synthesis involves the nucleophilic(18)F-fluorination of an alkylating agent and its GC purification, the subsequent(18)F-fluoroalkylation of a precursor molecule, the semipreparative HPLC purification of the(18)F-fluoroalkylated product, and its formulation for injection. We have optimized the duration and temperature of the(18)F-fluoroalkylation reaction and addressed the radiochemical stability of the formulated product. During the past 5 years (2013-2018), we have performed a total of 149 syntheses for clinical use with a 90% success rate. The activity yield of the formulated product has been 1.0 +/- 0.4 GBq starting from 11 +/- 2 GBq and the molar activity 600 +/- 300 GBq/mu mol at the end of synthesis.

Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.

Last updated on 2021-24-06 at 10:14